Zacks: Brokerages Anticipate Repare Therapeutics Inc. (NASDAQ:RPTX) Will Announce Earnings of -$0.86 Per Share

Analysts predict that Repare Therapeutics Inc. (NASDAQ:RPTX – Get Rating) will report earnings of ($0.89) per share for the current quarter, according to Zacks. Three analysts have made estimates for Repare Therapeutics’ earnings, with the lowest EPS estimate coming in at ($1.05) and the highest estimate coming in at ($0.80). Repare Therapeutics reported earnings per share of ($0.71) in the same quarter last year, which would suggest a negative year over year growth rate of 25.4%. The company is scheduled to issue its next earnings report on Monday, January 1st.

According to Zacks, analysts expect that Repare Therapeutics will report full year earnings of ($3.50) per share for the current year, with EPS estimates ranging from ($4.25) to ($2.92). For the next fiscal year, analysts expect that the business will report earnings of ($3.85) per share, with EPS estimates ranging from ($4.21) to ($3.17). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side analysts that follow Repare Therapeutics.

Repare Therapeutics (NASDAQ:RPTX – Get Rating) last posted its quarterly earnings data on Thursday, May 5th. The company reported ($0.83) earnings per share for the quarter, beating the consensus estimate of ($0.86) by $0.03. Repare Therapeutics had a negative net margin of 1,533.38% and a negative return on equity of 47.99%.

RPTX has been the subject of a number of research analyst reports. HC Wainwright reissued a “buy” rating and issued a $54.00 price target on shares of Repare Therapeutics in a research report on Tuesday, April 12th. Zacks Investment Research raised shares of Repare Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday. Piper Sandler dropped their price target on shares of Repare Therapeutics from $40.00 to $25.00 in a research report on Tuesday, April 12th. Stifel Nicolaus lowered shares of Repare Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, April 12th. Finally, The Goldman Sachs Group began coverage on shares of Repare Therapeutics in a research note on Thursday, March 17th. They issued a “buy” rating and a $43.00 price objective on the stock. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $44.50.

Shares of RPTX opened at $8.95 on Friday. Repare Therapeutics has a one year low of $8.75 and a one year high of $35.75. The company has a 50-day moving average of $12.50 and a two-hundred day moving average of $17.32. The stock has a market cap of $374.95 million, a price-to-earnings ratio of -2.92 and a beta of 0.89.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. BlackRock Inc. boosted its stake in Repare Therapeutics by 1.9% during the first quarter. BlackRock Inc. now owns 467,311 shares of the company’s stock worth $6,655,000 after buying an additional 8,680 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in Repare Therapeutics by 5.3% during the first quarter. JPMorgan Chase & Co. now owns 25,039 shares of the company’s stock worth $356,000 after buying an additional 1,253 shares in the last quarter. Sectoral Asset Management Inc. boosted its stake in Repare Therapeutics by 15.0% during the first quarter. Sectoral Asset Management Inc. now owns 237,785 shares of the company’s stock worth $3,386,000 after buying an additional 31,000 shares in the last quarter. Swiss National Bank boosted its stake in Repare Therapeutics by 7.0% during the first quarter. Swiss National Bank now owns 39,500 shares of the company’s stock worth $562,000 after buying an additional 2,600 shares in the last quarter. Finally, Mitsubishi UFJ Kokusai Asset Management Co. Ltd. boosted its stake in Repare Therapeutics by 9.5% during the first quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 11,580 shares of the company’s stock worth $165,000 after buying an additional 1,002 shares in the last quarter. Hedge funds and other institutional investors own 89.66% of the company’s stock.

Repare Therapeutics Company Profile (Get Rating)

Repare Therapeutics Inc, a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies that focuses on genomic instability, including DNA damage repair.

Featured Articles